Cronos Group (TSE:CRON) Shares Down 0.8% – Time to Sell?

Cronos Group Inc. (TSE:CRON) fell 0.8% on Tuesday . The stock traded as low as C$3.84 and last traded at C$3.89. Approximately 83,617 shares traded hands during trading, a decline of 51% from the average session volume of 169,685 shares. The stock had previously closed at C$3.92.

Analyst Ratings Changes

Separately, TD boosted their price objective on Cronos Group from C$4.50 to C$5.50 and gave the stock a “buy” rating in a research report on Tuesday, May 12th. Three equities research analysts have rated the stock with a Buy rating, According to MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of C$4.75.

Cronos Group Stock Performance

The company has a debt-to-equity ratio of 0.12, a quick ratio of 24.01 and a current ratio of 21.87. The company’s 50-day moving average price is C$3.82 and its 200-day moving average price is C$3.67. The firm has a market capitalization of C$1.45 billion, a PE ratio of -188.00, a PEG ratio of 0.12 and a beta of 1.13.

Cronos Group (TSE:CRON) last posted its earnings results on Monday, May 11th. The company reported C$0.06 EPS for the quarter. Cronos Group had a negative return on equity of 0.19% and a negative net margin of 1.29%.The firm had revenue of C$62.86 million for the quarter. On average, sell-side analysts expect that Cronos Group Inc. will post -0.26 earnings per share for the current year.

Cronos Group Company Profile

Cronos Group, headquartered in Toronto, Canada cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis to Poland and Germany. In addition, it has entered joint ventures in Israel, Colombia, and Australia to drive further international cultivation and distribution growth. In the U.S. the company directly sells hemp-derived CBD and has an option to acquire 10.5% of U.S.